Drug intelligence / Profile preview

doxazosin

Development stage: Approved
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral

Overview

Doxazosin is a selective alpha-1 adrenergic receptor blocker in the quinazoline class. It is primarily used to treat symptoms of benign prostatic hyperplasia (BPH) and hypertension. By blocking alpha-1 adrenergic receptors in vascular smooth muscle and the muscles of the bladder neck and prostate, doxazosin causes relaxation of these tissues. This leads to improved urine flow in BPH and reduced blood pressure in hypertension. Doxazosin is administered orally and is available as both immediate-release and extended-release formulations. It was patented in 1977 and introduced for medical use in 1988[1][2][4][5][7].

Brand names: CarduraCardura XLDoxaduraCascorCarduranLarbexRaporsinSlocin
Other names: doxazosin

Targets

ADRA1A (α1A)ADRA1B (α1B)ADRA1D (α1D)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on doxazosin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxazosin.

Explore the full profile